Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Recommendation of "Moderate Buy" by Analysts

Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $12.33.

Several brokerages have weighed in on HLN. Wall Street Zen upgraded Haleon from a "hold" rating to a "buy" rating in a report on Friday, June 6th. BNP Paribas upgraded shares of Haleon to a "strong-buy" rating in a research note on Tuesday, May 27th. Barclays reaffirmed an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target for the company in a research report on Friday, May 9th. Finally, BNP Paribas Exane raised shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective on the stock in a research note on Tuesday, May 27th.

Institutional Trading of Haleon

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC raised its holdings in shares of Haleon by 46.6% in the 2nd quarter. Parallel Advisors LLC now owns 26,252 shares of the company's stock worth $272,000 after purchasing an additional 8,348 shares during the period. Confluence Investment Management LLC boosted its stake in shares of Haleon by 3.4% during the 2nd quarter. Confluence Investment Management LLC now owns 84,413 shares of the company's stock valued at $875,000 after buying an additional 2,740 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Haleon by 6.7% in the 1st quarter. Rhumbline Advisers now owns 57,527 shares of the company's stock valued at $592,000 after purchasing an additional 3,625 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Haleon during the first quarter valued at approximately $1,767,000. Finally, Geneos Wealth Management Inc. lifted its stake in Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company's stock worth $50,000 after purchasing an additional 1,203 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Trading Down 1.1%

Shares of NYSE:HLN traded down $0.11 during mid-day trading on Friday, reaching $10.04. 12,782,005 shares of the company were exchanged, compared to its average volume of 9,583,519. The firm has a market cap of $45.10 billion, a price-to-earnings ratio of 25.74, a P/E/G ratio of 2.89 and a beta of 0.25. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.98 and a quick ratio of 0.78. The firm's 50-day simple moving average is $10.72 and its 200 day simple moving average is $10.16. Haleon has a 1 year low of $8.58 and a 1 year high of $11.42.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.